JWM
ALNY icon

Janiczek Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Janiczek Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$1.94K Hold
8
– – ﹤0.01% 860
2024
Q1 		$1.2K Hold
8
– – ﹤0.01% 922
2023
Q4 		$1.53K Hold
8
– – ﹤0.01% 882
2023
Q3 		$1.42K Hold
8
– – ﹤0.01% 875
2023
Q2 		$1.52K Hold
8
– – ﹤0.01% 796
2023
Q1 		$1.63K Hold
8
– – ﹤0.01% 788
2022
Q4 		$1.84K Hold
8
– – ﹤0.01% 785
2022
Q3 		$1K Hold
8
– – ﹤0.01% 799
2022
Q2 		$1K Hold
8
– – ﹤0.01% 821
2022
Q1 		$1K Hold
8
– – ﹤0.01% 817
2021
Q4 		$1K Hold
8
– – ﹤0.01% 872
2021
Q3 		$2K Hold
8
– – ﹤0.01% 793
2021
Q2 		$1K Hold
8
– – ﹤0.01% 802
2021
Q1 		$1K Hold
8
– – ﹤0.01% 766
2020
Q4 		$1K Buy
+8
New +$1.07K ﹤0.01% 708

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janiczek Wealth Management's ALNY Position: Q2 2024 in Review

Janiczek Wealth Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2024 at 8 shares worth $1.94K. The position accounts for ﹤0.01% of the portfolio, ranked #860.

Janiczek Wealth Management first reported a position in ALNY in Q4 2020 and has held it in 15 quarters since. The position peaked at $2K in Q3 2021. 521 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

  • Janiczek Wealth Management held 8 shares of Alnylam Pharmaceuticals worth $1.94K as of Q2 2024.
  • Janiczek Wealth Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2024.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Janiczek Wealth Management's portfolio in Q2 2024, its #860 holding.
  • Janiczek Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2020 and has held it in 15 quarters since.
  • Janiczek Wealth Management's Alnylam Pharmaceuticals position peaked at $2K in Q3 2021.
  • 521 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Janiczek Wealth Management's 13F filing for Q2 2024, filed 25 Jul 2024.